Actuate Therapeutics, Inc./$ACTU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Actuate Therapeutics, Inc.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Ticker
$ACTU
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
10
ISIN
US0050831009
Website
ACTU Metrics
BasicAdvanced
$126M
-
-$1.97
-
-
Price and volume
Market cap
$126M
52-week high
$11.99
52-week low
$6.02
Average daily volume
79K
Financial strength
Current ratio
0.464
Quick ratio
0.425
Interest coverage (TTM)
-1,269.95%
Profitability
Management effectiveness
Return on assets (TTM)
-413.43%
Return on equity (TTM)
286.54%
Valuation
Price to book
-24.72
Price to tangible book (TTM)
-24.72
Price to free cash flow (TTM)
-3.905
Free cash flow yield (TTM)
-25.61%
Free cash flow per share (TTM)
-164.92%
Growth
Earnings per share change (TTM)
-89.49%
ACTU News
AllArticlesVideos
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
GlobeNewsWire·2 days ago
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
GlobeNewsWire·6 days ago
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Actuate Therapeutics, Inc. stock?
Actuate Therapeutics, Inc. (ACTU) has a market cap of $126M as of June 26, 2025.
What is the P/E ratio for Actuate Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Actuate Therapeutics, Inc. (ACTU) stock is 0 as of June 26, 2025.
Does Actuate Therapeutics, Inc. stock pay dividends?
No, Actuate Therapeutics, Inc. (ACTU) stock does not pay dividends to its shareholders as of June 26, 2025.
When is the next Actuate Therapeutics, Inc. dividend payment date?
Actuate Therapeutics, Inc. (ACTU) stock does not pay dividends to its shareholders.
What is the beta indicator for Actuate Therapeutics, Inc.?
Actuate Therapeutics, Inc. (ACTU) does not currently have a Beta indicator.